|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM291342949 |
| 003 |
DE-627 |
| 005 |
20250224111635.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.11.016
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0971.xml
|
| 035 |
|
|
|a (DE-627)NLM291342949
|
| 035 |
|
|
|a (NLM)30503407
|
| 035 |
|
|
|a (PII)S1521-6616(18)30242-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xia, Muye
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.10.2019
|
| 500 |
|
|
|a Date Revised 28.10.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a In this study, we investigated whether plasma cytokine/chemokine levels could predict HBsAg loss or clinical relapse (CR) after stopping nucleos(t)ides analogue (NA) treatment. Theplasma cytokines/chemokines levels were measured at 0, 4, 8, 12, 24 and 48 weeks after NA discontinuation by using the enzyme-linked immunoassay (ELISA) kit. Cox regression analysis revealed that CXCL13 level at the end of treatment (EOT) was an independent predictor for CR (HR 0.26, p < 0.001) and HBsAg loss (HR 3.01, p = 0.008) after treatment cessation. Among the patients with EOT CXCL13 level < 80 pg/ml, the cumulative incidences of CR and HBsAg loss were 65% and 0% at 4 years, respectively. As for the patients with EOT CXCL13 level ≥ 1000 pg/ml, 47.5% cases had HBsAg loss. Our study showed that EOT CXCL13 level was associated with off-treatment response, which may be used to guide cessation of NA treatment in clinical practice
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Observational Study
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a CXCL13
|
| 650 |
|
4 |
|a Clinical relapse
|
| 650 |
|
4 |
|a Discontinuation
|
| 650 |
|
4 |
|a HBsAg loss
|
| 650 |
|
4 |
|a Nucleos(t)ide analogue
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a CXCL13 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CXCL13
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Hepatitis B Surface Antigens
|2 NLM
|
| 650 |
|
7 |
|a Nucleosides
|2 NLM
|
| 700 |
1 |
|
|a Liao, Guichan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Hongjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Yin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Rong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xiaoyong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peng, Jie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 198(2019) vom: 01. Jan., Seite 31-38
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:198
|g year:2019
|g day:01
|g month:01
|g pages:31-38
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.11.016
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 198
|j 2019
|b 01
|c 01
|h 31-38
|